Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated:  12/31/1969
Jackson Madison County General Hospital
mi
from
Jacksonville, TN
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated: 12/31/1969
Jackson Madison County General Hospital
mi
from
Jacksonville, TN
Click here to add this to my saved trials
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated:  12/31/1969
Texas Oncology P A
mi
from
Arlington, TX
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated: 12/31/1969
Texas Oncology P A
mi
from
Arlington, TX
Click here to add this to my saved trials
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated:  12/31/1969
Texas Oncology P A
mi
from
Beaumont, TX
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated: 12/31/1969
Texas Oncology P A
mi
from
Beaumont, TX
Click here to add this to my saved trials
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated:  12/31/1969
Texas Oncology P A
mi
from
Denton, TX
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated: 12/31/1969
Texas Oncology P A
mi
from
Denton, TX
Click here to add this to my saved trials
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, P.A.
mi
from
Flower Mound, TX
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, P.A.
mi
from
Flower Mound, TX
Click here to add this to my saved trials
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Memorial City
mi
from
Houston, TX
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Memorial City
mi
from
Houston, TX
Click here to add this to my saved trials
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated:  12/31/1969
Texas Oncology
mi
from
Paris, TX
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated: 12/31/1969
Texas Oncology
mi
from
Paris, TX
Click here to add this to my saved trials
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated:  12/31/1969
Texas Oncology P A
mi
from
Plano, TX
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated: 12/31/1969
Texas Oncology P A
mi
from
Plano, TX
Click here to add this to my saved trials
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated:  12/31/1969
Texas Oncology
mi
from
Tyler, TX
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated: 12/31/1969
Texas Oncology
mi
from
Tyler, TX
Click here to add this to my saved trials
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated:  12/31/1969
Texas Oncology P A
mi
from
Waco, TX
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated: 12/31/1969
Texas Oncology P A
mi
from
Waco, TX
Click here to add this to my saved trials
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, P.A.
mi
from
Webster, TX
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, P.A.
mi
from
Webster, TX
Click here to add this to my saved trials
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, PA
mi
from
Wichita Falls, TX
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, PA
mi
from
Wichita Falls, TX
Click here to add this to my saved trials
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated:  12/31/1969
Kadlec Clinic Hematology and Oncology
mi
from
Kennewick, WA
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated: 12/31/1969
Kadlec Clinic Hematology and Oncology
mi
from
Kennewick, WA
Click here to add this to my saved trials
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated:  12/31/1969
Carolina Blood and Cancer Care
mi
from
Rock Hill, SC
Multiple Myeloma Patient Registry
Multiple Myeloma Patient Registry
Status: Enrolling
Updated: 12/31/1969
Carolina Blood and Cancer Care
mi
from
Rock Hill, SC
Click here to add this to my saved trials
Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients
Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients
Status: Enrolling
Updated:  12/31/1969
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients
Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients
Status: Enrolling
Updated: 12/31/1969
Ann & Robert H. Lurie Children's Hospital of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Nitrate Supplementation and Muscle Blood Flow
Nitric Oxide Bioavailability and Dynamics of Blood Flow and Vasodilation With Age
Status: Enrolling
Updated:  12/31/1969
Medical Education Building
mi
from
Iowa City, IA
Nitrate Supplementation and Muscle Blood Flow
Nitric Oxide Bioavailability and Dynamics of Blood Flow and Vasodilation With Age
Status: Enrolling
Updated: 12/31/1969
Medical Education Building
mi
from
Iowa City, IA
Click here to add this to my saved trials
Dose Confirmation Trial of AAV5-hFIXco-Padua
Phase IIb, Open-label, Single-dose, Single-arm, Multi-center Trial to Confirm the Factor IX Activity Level of the Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Status: Enrolling
Updated:  12/31/1969
University of California-Davis
mi
from
Sacramento, CA
Dose Confirmation Trial of AAV5-hFIXco-Padua
Phase IIb, Open-label, Single-dose, Single-arm, Multi-center Trial to Confirm the Factor IX Activity Level of the Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Status: Enrolling
Updated: 12/31/1969
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
Dose Confirmation Trial of AAV5-hFIXco-Padua
Phase IIb, Open-label, Single-dose, Single-arm, Multi-center Trial to Confirm the Factor IX Activity Level of the Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Status: Enrolling
Updated:  12/31/1969
University of California, San Diego
mi
from
San Diego, CA
Dose Confirmation Trial of AAV5-hFIXco-Padua
Phase IIb, Open-label, Single-dose, Single-arm, Multi-center Trial to Confirm the Factor IX Activity Level of the Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Status: Enrolling
Updated: 12/31/1969
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Dose Confirmation Trial of AAV5-hFIXco-Padua
Phase IIb, Open-label, Single-dose, Single-arm, Multi-center Trial to Confirm the Factor IX Activity Level of the Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Dose Confirmation Trial of AAV5-hFIXco-Padua
Phase IIb, Open-label, Single-dose, Single-arm, Multi-center Trial to Confirm the Factor IX Activity Level of the Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Dose Confirmation Trial of AAV5-hFIXco-Padua
Phase IIb, Open-label, Single-dose, Single-arm, Multi-center Trial to Confirm the Factor IX Activity Level of the Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Status: Enrolling
Updated:  12/31/1969
Los Angeles Orthopedic Hospital
mi
from
Los Angeles, CA
Dose Confirmation Trial of AAV5-hFIXco-Padua
Phase IIb, Open-label, Single-dose, Single-arm, Multi-center Trial to Confirm the Factor IX Activity Level of the Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Status: Enrolling
Updated: 12/31/1969
Los Angeles Orthopedic Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD
A Phase IIa Study of Recombinant Human Interleukin-22 IgG2-Fc (F 652) in Combination With Systemic Corticosteroids for the Treatment of Newly Diagnosed Grade II-IV Lower Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) in Hematopoietic Stem Cell Transplantation Recipients (HSCT)
Status: Enrolling
Updated:  12/31/1969
MSKCC
mi
from
New York, NY
Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD
A Phase IIa Study of Recombinant Human Interleukin-22 IgG2-Fc (F 652) in Combination With Systemic Corticosteroids for the Treatment of Newly Diagnosed Grade II-IV Lower Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) in Hematopoietic Stem Cell Transplantation Recipients (HSCT)
Status: Enrolling
Updated: 12/31/1969
MSKCC
mi
from
New York, NY
Click here to add this to my saved trials
Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD
A Phase IIa Study of Recombinant Human Interleukin-22 IgG2-Fc (F 652) in Combination With Systemic Corticosteroids for the Treatment of Newly Diagnosed Grade II-IV Lower Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) in Hematopoietic Stem Cell Transplantation Recipients (HSCT)
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD
A Phase IIa Study of Recombinant Human Interleukin-22 IgG2-Fc (F 652) in Combination With Systemic Corticosteroids for the Treatment of Newly Diagnosed Grade II-IV Lower Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) in Hematopoietic Stem Cell Transplantation Recipients (HSCT)
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD
A Phase IIa Study of Recombinant Human Interleukin-22 IgG2-Fc (F 652) in Combination With Systemic Corticosteroids for the Treatment of Newly Diagnosed Grade II-IV Lower Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) in Hematopoietic Stem Cell Transplantation Recipients (HSCT)
Status: Enrolling
Updated:  12/31/1969
City of Hope
mi
from
Duarte, CA
Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD
A Phase IIa Study of Recombinant Human Interleukin-22 IgG2-Fc (F 652) in Combination With Systemic Corticosteroids for the Treatment of Newly Diagnosed Grade II-IV Lower Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) in Hematopoietic Stem Cell Transplantation Recipients (HSCT)
Status: Enrolling
Updated: 12/31/1969
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Study of rFVIIIFc for ITI in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies
A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed With rFVIIIFc Within a Timeframe of 60 Weeks in Severe Haemophilia A Patients With Inhibitors Who Have Failed Previous Immune Tolerance Induction Therapies
Status: Enrolling
Updated:  12/31/1969
Swedish Orphan Biovitrum Research Site
mi
from
Atlanta, GA
Study of rFVIIIFc for ITI in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies
A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed With rFVIIIFc Within a Timeframe of 60 Weeks in Severe Haemophilia A Patients With Inhibitors Who Have Failed Previous Immune Tolerance Induction Therapies
Status: Enrolling
Updated: 12/31/1969
Swedish Orphan Biovitrum Research Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of rFVIIIFc for ITI in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies
A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed With rFVIIIFc Within a Timeframe of 60 Weeks in Severe Haemophilia A Patients With Inhibitors Who Have Failed Previous Immune Tolerance Induction Therapies
Status: Enrolling
Updated:  12/31/1969
Swedish Orphan Biovitrum Research site
mi
from
Brussels,
Study of rFVIIIFc for ITI in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies
A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed With rFVIIIFc Within a Timeframe of 60 Weeks in Severe Haemophilia A Patients With Inhibitors Who Have Failed Previous Immune Tolerance Induction Therapies
Status: Enrolling
Updated: 12/31/1969
Swedish Orphan Biovitrum Research site
mi
from
Brussels,
Click here to add this to my saved trials
Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Participants With Relapsed Multiple Myeloma
Phase 2 Trial of Pembrolizumab, Ixazomib, and Dexamethasone for Relapsed Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Participants With Relapsed Multiple Myeloma
Phase 2 Trial of Pembrolizumab, Ixazomib, and Dexamethasone for Relapsed Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
IRF-PAI Functional Outcomes Data(With FIM Instrument Variables)
IRF-PAI Functional Outcomes Data(With FIM Instrument Variables)
Status: Enrolling
Updated:  12/31/1969
UDSMR
mi
from
Buffalo, NY
IRF-PAI Functional Outcomes Data(With FIM Instrument Variables)
IRF-PAI Functional Outcomes Data(With FIM Instrument Variables)
Status: Enrolling
Updated: 12/31/1969
UDSMR
mi
from
Buffalo, NY
Click here to add this to my saved trials
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
A Phase I Trial of Volasertib (BI 6727), an Intravenous Polo-Like Kinase Inhibitor, in Combination With "7+3" Induction Chemotherapy for Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
A Phase I Trial of Volasertib (BI 6727), an Intravenous Polo-Like Kinase Inhibitor, in Combination With "7+3" Induction Chemotherapy for Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
A Phase I Trial of Volasertib (BI 6727), an Intravenous Polo-Like Kinase Inhibitor, in Combination With "7+3" Induction Chemotherapy for Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
A Phase I Trial of Volasertib (BI 6727), an Intravenous Polo-Like Kinase Inhibitor, in Combination With "7+3" Induction Chemotherapy for Patients With Acute Myeloid Leukemia
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  12/31/1969
Tunnell Cancer Center at Beebe Medical Center
mi
from
Lewes, DE
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 12/31/1969
Tunnell Cancer Center at Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  12/31/1969
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 12/31/1969
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  12/31/1969
University of Illinois Cancer Center
mi
from
Chicago, IL
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 12/31/1969
University of Illinois Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  12/31/1969
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 12/31/1969
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  12/31/1969
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 12/31/1969
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  12/31/1969
Union Hospital Cancer Program at Union Hospital
mi
from
Elkton, MD
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 12/31/1969
Union Hospital Cancer Program at Union Hospital
mi
from
Elkton, MD
Click here to add this to my saved trials
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  12/31/1969
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 12/31/1969
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  12/31/1969
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 12/31/1969
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  12/31/1969
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 12/31/1969
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  12/31/1969
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 12/31/1969
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  12/31/1969
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 12/31/1969
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
A Phase II Trial Of Intravenous Pentostatin For The Treatment Of Patients With Refractory Chronic Graft-Versus-Host Disease
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
Status: Enrolling
Updated:  12/31/1969
Hematology/Oncology Associates of Northern New Jersey, P.A.
mi
from
Morristown, NJ
A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
Status: Enrolling
Updated: 12/31/1969
Hematology/Oncology Associates of Northern New Jersey, P.A.
mi
from
Morristown, NJ
Click here to add this to my saved trials
Stem Cell Transplantation for Patients With Cancers of the Blood
Selective Depletion of Alloreacting T Cells Using a Photodepletion Technique to Prevent GVHD After HLA-Matched Peripheral Blood Stem Cell Transplantation for Subjects With Hematologic Malignancies
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Stem Cell Transplantation for Patients With Cancers of the Blood
Selective Depletion of Alloreacting T Cells Using a Photodepletion Technique to Prevent GVHD After HLA-Matched Peripheral Blood Stem Cell Transplantation for Subjects With Hematologic Malignancies
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Status: Enrolling
Updated:  12/31/1969
Swedish Cancer Institute
mi
from
Seattle, WA
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Status: Enrolling
Updated: 12/31/1969
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Status: Enrolling
Updated:  12/31/1969
UCSF Medical Center
mi
from
San Francisco, CA
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Status: Enrolling
Updated: 12/31/1969
UCSF Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials